Browse > Article
http://dx.doi.org/10.4062/biomolther.2012.088

Down-Regulation of Survivin by Nemadipine-A Sensitizes Cancer Cells to TRAIL-Induced Apoptosis  

Park, Seong Ho (Ilsong Institute for Life Science, Hallym University)
Park, So Jung (Graduate School of East-West Medical Science, Kyung Hee University)
Kim, Joo-Oh (Graduate School of East-West Medical Science, Kyung Hee University)
Shin, Ji Hyun (Graduate School of East-West Medical Science, Kyung Hee University)
Kim, Eun Sung (Graduate School of East-West Medical Science, Kyung Hee University)
Jo, Yoon Kyung (Graduate School of East-West Medical Science, Kyung Hee University)
Kim, Jae-Sung (Division of Radiation Cancer Research, Korea Institute of Radiological and Medical Science)
Park, So Jung (Asan Institute for Life Science, Asan Medical Center)
Jin, Dong-Hoon (Asan Institute for Life Science, Asan Medical Center)
Hwang, Jung Jin (Asan Institute for Life Science, Asan Medical Center)
Lee, Seung Jin (Asan Institute for Life Science, Asan Medical Center)
Jeong, Seong-Yun (Asan Institute for Life Science, Asan Medical Center)
Lee, Chaeyoung (Department of Bioinformatics and Life Science, Soongsil University)
Kim, InKi (Asan Institute for Life Science, Asan Medical Center)
Cho, Dong-Hyung (Graduate School of East-West Medical Science, Kyung Hee University)
Publication Information
Biomolecules & Therapeutics / v.21, no.1, 2013 , pp. 29-34 More about this Journal
Abstract
The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor family of cytokines. TRAIL selectively induces apoptotic cell death in various tumors and cancer cells, but it has little or no toxicity in normal cells. Agonism of TRAIL receptors has been considered to be a valuable cancer-therapeutic strategy. However, more than 85% of primary tumors are resistant to TRAIL, emphasizing the importance of investigating how to overcome TRAIL resistance. In this report, we have found that nemadipine-A, a cell-permeable L-type calcium channel inhibitor, sensitizes TRAIL-resistant cancer cells to this ligand. Combination treatments using TRAIL with nemadipine-A synergistically induced both the caspase cascade and apoptotic cell death, which were blocked by a pan caspase inhibitor (zVAD) but not by autophagy or a necrosis inhibitor. We further found that nemadipine-A, either alone or in combination with TRAIL, notably reduced the expression of survivin, an inhibitor of the apoptosis protein (IAP) family of proteins. Depletion of survivin by small RNA interference (siRNA) resulted in increased cell death and caspase activation by TRAIL treatment. These results suggest that nemadipine-A potentiates TRAIL-induced apoptosis by down-regulation of survivin expression in TRAIL resistant cells. Thus, combination of TRAIL with nemadipine-A may serve a new therapeutic scheme for the treatment of TRAIL resistant cancer cells, suggesting that a detailed study of this combination would be useful.
Keywords
TRAIL; Nemadipine-A; Sensitization; Cell death; H1299 cells;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Abdulghani, J. and El-Deiry, W. S. (2010) TRAIL receptor signaling and therapeutics. Expert Opin. Ther. Targets 14, 1091-1108.   DOI   ScienceOn
2 Altieri, D. C. (2010) Survivin and IAP proteins in cell-death mechanisms. Biochem. J. 430, 199-205.   DOI   ScienceOn
3 Ammann, J. U., Haag, C., Kasperczyk, H., Debatin, K. M. and Fulda, S. (2009) Sensitization of neuroblastoma cells for TRAIL-induced apoptosis by NF-kappaB inhibition. Int. J. Cancer 124, 1301-1311.   DOI   ScienceOn
4 Bellail, A. C., Qi, L., Mulligan, P., Chhabra, V. and Hao, C. (2009) TRAIL agonists on clinical trials for cancer therapy; the promises and the challenges. Rev. Recent Clin. Trials 4, 34-41.   DOI   ScienceOn
5 Cho, D. H., Jo, Y. K., Hwang, J. J., Lee, Y. M., Roh, S. A. and Kim, J. C. (2009) Caspase-mediated cleavage of ATG6/Beclin-1 links apoptosis to autophagy in HeLa cells. Cancer Lett. 274, 95-100.   DOI   ScienceOn
6 Frokjaer-Jensen, C., Kindt, K. S., Kerr, R. A., Suzuki, H., Melnik-Martinez, K., Gerstbreih, B., Driscol, M. and Schafer, W. R. (2006) Effects of voltage-gated calcium channel subunit genes on calcium influx in cultured C. elegans mechanosensory neurons. J. Neurobiol. 66, 1125-1139.   DOI   ScienceOn
7 Hanahan, D. and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70.   DOI   ScienceOn
8 Hou, W., Han, J., Lu, C., Goldstein, L. A. and Rabinowich, H. (2008) Enhancement of tumor-TRAIL susceptibility by modulation of autophagy. Autophagy 4, 940-943.   DOI
9 Hui, K., Kwok, T. C., Kostelecki, W., Leen, J., Roy, P. J. and Feng, Z. P. (2009) Differential sensitivities of CaV1.2 IIS5-S6 mutants to 1,4-dihydropyridine analogs. Eur. J. Pharmacol. 602, 255-261.   DOI   ScienceOn
10 Jiang, C. C., Chen, L. H., Gillespie, S., Kiejda, K. A., Mhaidat, N., Wang, Y. F., Thorne, R., Zhang, X. D. and Hersey, P. (2007) Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. Cancer Res. 67, 5880-5888.   DOI   ScienceOn
11 Jin, C. Y., Moon, D. O., Lee, J. D., Heo, M. S., Choi, Y. H., Lee, C. M., Park, Y. M. and Kim, G. Y. (2007) Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis through downregulation of ERK and Akt in lung adenocarcinoma A549 cells. Carcinogenesis 28, 1058-1066.
12 Johnstone, R. W., Frew, A. J. and Smyth, M. J. (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 8, 782-798.   DOI   ScienceOn
13 Jouan-Lanhouet, S., Arshad, M. I., Piquet-Pellorce, C., Martin-Chouly, C., Le Moigne-Muller, G., Van Herreweghe, F., Takahashi, N., Sergent, O., Lagadic-Gossmann, D., Vandenabeele, P., Samson, M. and Dimanche-Boitrel, M. T. (2012) TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation. Cell Death Differ. 19, 2003-2014.   DOI   ScienceOn
14 Kaddour-Djebbar, I., Lakshmikanthan, V., Shirley, R. B., Ma, Y., Lewis, R. W. and Kumar, M.V. (2006) Therapeutic advantage of combining calcium channel blockers and TRAIL in prostate cancer. Mol. Cancer Ther. 5, 1958-1966.   DOI   ScienceOn
15 Kim, Y. and Seol, D. W. (2003) TRAIL, a mighty apoptosis inducer. Mol. Cells 15, 283-293.
16 Kanwar, J. R., Kamalapuram, S. K. and Kanwar, R. K. (2011) Targeting survivin in cancer: the cell-signalling perspective. Drug Discov. Today 16, 485-494.   DOI   ScienceOn
17 Kawasaki, H., Toyoda, M., Shinohara, H., Okuda, J., Watanabe, I., Yamamoto, T., Tanaka, K., Tenjo, T. and Tanigawa, N. (2001) Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 91, 2026-2032.   DOI   ScienceOn
18 Kim, I. K., Chung, C. W., Woo, H. N., Hong, G. S., Nagata, S. and Jung, Y. K. (2000) Reconstitution of caspase-8 sensitizes JB6 cells to TRAIL. Biochem. Biophys. Res. Commun. 277, 311-316.   DOI   ScienceOn
19 Kim, S., Kang, J., Qiao, J., Thomas, R. P., Evers, B. M. and Chung, D. H. (2004) Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas. J. Pediatr. Surg. 39, 516-521.   DOI   ScienceOn
20 Kwok, T. C., Ricker, N., Fraser, R., Chan, A. W., Burns, A., Stanley, E. F., McCourt, P., Cutler, S. R. and Roy, P. J. (2006) A small-molecule screen in C. elegans yields a new calcium channel antagonist. Nature 441, 91-95.   DOI   ScienceOn
21 Lamy, V., Bousserouel, S., Gosse, F., Minker, C., Lobstein, A. and Raul, F. (2011) Lupulone triggers p38 MAPK-controlled activation of p53 and of the TRAIL receptor apoptotic pathway in human colon cancer-derived metastatic cells. Oncol. Rep. 26, 109-114.
22 Li, S.S., Yang, S., Wang, S., Yang, X. M., Tang, Q. L. and Wang, S. H. (2011) Latent membrane protein 1 mediates the resistance of nasopharyngeal carcinoma cells to TRAIL-induced apoptosis by activation of the PI3K/Akt signaling pathway. Oncol. Rep. 26, 1573-1579.
23 Lu, M., Strohecker, A., Chen, F., Kwan, T., Bosman, J., Jordan, V. C. and Cryns, V. L. (2008) Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Clin. Cancer Res. 14, 3168-3176.   DOI   ScienceOn
24 Mahalingam, D., Szegezdi, E., Keane, M., de Jong, S. and Samali A. (2009) TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev. 35, 280-288.   DOI   ScienceOn
25 Oh, B., Park, S., Pak, J. H. and Kim, I. (2012) Downregulation of Mcl-1 by daunorubicin pretreatment reverses resistance of breast cancer cells to TNF-related apoptosis-inducing ligand. Biochem. Biophys. Res. Commun. 422, 42-47.   DOI   ScienceOn
26 Okamoto, K., Okamoto, I., Okamoto, W., Tanaka, K., Takezawa, K., Kuwata, K., Yamaguchi, H., Nishio, K. and Nakagawa, K. (2010) Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res. 70, 10402-10410.   DOI   ScienceOn
27 Raviv, Z., Zilberberg, A., Cohen, S., Reischer-Pelech, D., Horrix, C., Berger, M. R., Rosin-Arbesfeld R. and Flescher E. (2011) Methyl jasmonate down-regulates survivin expression and sensitizes colon carcinoma cells towards TRAIL-induced cytotoxicity. Br. J. Pharmacol. 164, 1433-1444.   DOI   ScienceOn
28 Ortiz, J. and Chou, L. L. (2012) Calcium up-regulated survivin expression and associated osteogenesis of normal human osteoblasts. J. Biomed. Mater. Res. 100, 1770-1776.
29 Park, S. J., Park, S. H., Kim, J., Kim, J. H., Park, S. J., Hwang, J. J., Jin D.H., Jeong S., Lee S.J., Kim J.C., Kim I. and Cho D.H. (2012) Carnitine sensitizes TRAIL-resistant cancer cells to TRAIL-induced apoptotic cell death through the up-regulation of Bax. Biochem. Biophys. Res. Commun. 428, 185-190.   DOI   ScienceOn
30 Pennati, M., Colella, G., Folini, M., Citti, L., Daidone, M. G. and Zaffaroni, N. (2002) Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J. Clin. Invest. 109, 285-286.   DOI
31 Ryan, B. M., O'Donovan, N. and Duffy, M. J. (2009) Survivin: a new target for anti-cancer therapy. Cancer Treat. Rev. 35, 553-562.   DOI   ScienceOn
32 Stout, R. F. Jr. and Parpura, V. (2011) Voltage-gated calcium channel types in cultured C. elegans CEPsh glial cells. Cell Calcium 50, 98-108.   DOI   ScienceOn
33 Sung, E. S., Kim, A., Park, J. S., Chung, J., Kwon, M. H. and Kim Y. S. (2010) Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. Apoptosis 10, 1256-1269.
34 Sung, E. S., Park, K. J., Choi, H. J., Kim, C. H. and Kim, Y. S. (2012) The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells. Exp. Cell Res. 318, 1564-1576.   DOI   ScienceOn
35 Zhang, X., Inukai, T., Akahane, K., Hirose, K., Kuroda, I., Honna, H., Goi, K., Kagami, K., Tauchi, T., Yagita, H. and Sugita, K. (2011) Endoplasmic reticulum stress inducers, but not imatinib, sensitize Philadelphia chromosome-positive leukemia cells to TRAIL-mediated apoptosis. Leuk. Res. 35, 940-949.   DOI   ScienceOn
36 Tamm, I., Wang, Y., Sausville, E., Scudiero, D. A., Vigna, N., Oltersdorf, T. and Reed, J. C. (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58, 5315-5320.
37 Vader, G., Kauw, J. J., Medema, R. H. and Lens, S. M. (2006) Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody. EMBO Rep. 7, 85-92.   DOI   ScienceOn
38 van Geelen, C. M., Pennarun, B., Le, P.T., de Vries, E. G. and de Jong, S. (2011) Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5. BMC Cancer 11, 39.   DOI   ScienceOn